Research programme: amniotic stem cell therapies - Creative Medical Technology Holdings

Drug Profile

Research programme: amniotic stem cell therapies - Creative Medical Technology Holdings

Alternative Names: AmnioStem; AmnioStem universal donor stem cell; Amniotic fluid derived stem cell; Amniotic fluid stem cells

Latest Information Update: 02 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Creative Medical Technology Holdings
  • Class Cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Primary ovarian insufficiency; Stroke

Most Recent Events

  • 24 May 2017 Creative Medical Technology files for patent protection for amniotic stem cell therapies covering means of suppressing inflammation associated with stroke
  • 04 Apr 2017 Creative Medical Technology files for patent protection for amniotic fluid derived stem cells therapy for radiation toxicity
  • 13 Dec 2016 Creative Medical Technology Holdings files for patent protection with the United States Patent and Trademark Office for amniotic stem cell therapies in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top